Targeted Activation of Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Rapidly Suppresses Inflammation Through Inhibition of Toll-Like Receptor 4/Nuclear Factor-kappa B (TLR4/NF-kappa B) Pathway and Further Shifts Advanced Atheroma Into a Stable Phenotype
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim Jin Won | - |
dc.date.accessioned | 2021-08-27T12:56:13Z | - |
dc.date.available | 2021-08-27T12:56:13Z | - |
dc.date.created | 2021-04-22 | - |
dc.date.issued | 2019-11-18 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/7886 | - |
dc.publisher | AHA(American Heart Association) | - |
dc.title | Targeted Activation of Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Rapidly Suppresses Inflammation Through Inhibition of Toll-Like Receptor 4/Nuclear Factor-kappa B (TLR4/NF-kappa B) Pathway and Further Shifts Advanced Atheroma Into a Stable Phenotype | - |
dc.title.alternative | Targeted Activation of Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Rapidly Suppresses Inflammation Through Inhibition of Toll-Like Receptor 4/Nuclear Factor-kappa B (TLR4/NF-kappa B) Pathway and Further Shifts Advanced Atheroma Into a Stable Phenotype | - |
dc.type | Conference | - |
dc.contributor.affiliatedAuthor | Kim Jin Won | - |
dc.identifier.bibliographicCitation | AHA(American Heart Association) | - |
dc.relation.isPartOf | AHA(American Heart Association) | - |
dc.relation.isPartOf | AHA(American Heart Association) | - |
dc.citation.title | AHA(American Heart Association) | - |
dc.citation.conferencePlace | US | - |
dc.citation.conferenceDate | 2019-11-16 | - |
dc.type.rims | CONF | - |
dc.description.journalClass | 1 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.